11&bgr;-HALOGEN-7&agr;-SUBSTITUTED ESTRATRIENES, PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE 11&bgr;-HALOGEN-7&agr;-SUBSTITUTED ESTRATRIENES AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS

US6780855B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Rolf Bohlmann · Berlin, DE
• Nikolaus Heinrich · Berlin, DE
• Helmut Hofmeister · Berlin, DE
• Jorg Kroll · Berlin, DE
• Hermann Kunzer · Hermeskeil, DE
• Gerhard Sauer · Berlin, DE
• Ludwig Zorn · Berlin, DE
• Karl-Heinrich Fritzemeier · Berlin, DE
• Monika Lessl · Berlin, DE
• Rosemarie Lichtner · Berlin, DE
• Yukishige Nishino · Berlin, DE
• Karsten Parczyk · Berlin, DE
• Martin Schneider · Remchingen, DE

Key dates

• Filing date: Dec 2, 1999
• Grant date: Aug 24, 2004
• Expiry date: Dec 2, 2019

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07J43/003
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention describes the new 11&bgr;-halogen-7&agr;-substituted estratrienes of general formula I in whichR11 is a fluorine or chlorine atom, and the other substituents have the meanings that are explained in more detail in the description.The compounds have antiestrogenic properties or tissue-selective estrogenic properties and are suitable for the production of pharmaceutical agents.